Highlighted Research

Dissertation Work

Appraising the Value of New and Emerging Technologies and Approaches for Serosurveillance in Low- and Middle-Income Countries

I used a combination of economic and qualitative research techniques to:

Compare the costs of using specimens taken from resource-intensive door-to-door serosurveys versus using "residual specimens" which are those that have already been collected for routine purposes and testing (but which might be more biased because the average child who presents to hospitals and clinics might be different than the average child in the community) for identifying measles immunity gaps.
Compare the cost-effectiveness of using rapid diagnostic tests to identify whether a child has measles or not when they present to health facilities versus using enzyme-linked immunosorbent assays (ELISAs), which is often used for diagnosis of measles cases but which requires the sample to be transported (at times long distances) to central laboratories, potentially adding substantial transportation and labor costs.
Determine what different experts think about the value, opportunities, and challenges to adopting an underutilized technology, the multiplex bead assay (MBAs), that functions similar to ELISAs but can produce data on the presence of antibodies to many more antigens and pathogens with the same amount of blood or serum.

Access to Medicine

Selected work from the Access to Medicine Foundation (2018-2020)

From 2018 to 2020 I was the Research and Development (R&D) Researcher for the Access to Medicine Index at the Access to Medicine Foundation, a non-profit research organization which monitors what some of the largest pharmaceutical companies are or are not doing to expand access to key health technologies for patients living in low- and middle-income countries. Over this time, I contributed to several projects within and beyond the Index team. Some of these projects are highlighted below.

Access to Medicine Index 10 Year Analysis.pdf

Are pharmaceutical companies making progress when it comes to global health?

The Foundation's first longitudinal report, collating findings over a decade of research from six iterations of the Access to Medicine Index. I was co-lead author and the Research Team project lead for this report.

My responsibilities included methodology development ownership of two sections of the report, figure development and management, editorial and content review, and coordination of fact checking statements linked to the twenty companies across the entire report.

2018 Access to Medicine Index.pdf

2018 Access to Medicine Index

The Access to Medicine Index is the flagship publication for the Access to Medicine Foundation and is published every two years. This publication assesses the practices and commitments of 20 of the largest multinational pharmaceutical companies.

As the R&D Researcher, I was responsible for maintaining and identifying trends and important projects in each company's R&D pipeline, assessing how companies planned ahead for access to these innovations, and highlighting gaps where R&D pipelines were dwindling. I contributed to two of the three key findings and three of the six figure-led analyses.

Page updated

Google Sites

Report abuse